BioStock: Coegin Pharma takes key steps for growth during Q3
Q3 was an active quarter for Coegin Pharma and its pursuit to address a large unmet medical need in cancer and chronic inflammatory diseases. Highlighted in the company’s interim report are the initiation of the COAK study with AVX001 gel in actinic keratosis patients, the merger with Swedish biotech Follicum, and the development of a new candidate for the treatment of leukaemia and potentially other cancers.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/